<DOC>
	<DOCNO>NCT00165607</DOCNO>
	<brief_summary>To investigate new incidence preventive effect menatetrenone vertebral fracture patient osteoporosis randomly assign either treatment arm receive daily dose calcium supplement monotherapy ( calcium monotherapy group ) menatetrenone plus calcium supplement combination therapy ( menatetrenone combo therapy group ) 36 month , follow 12-month follow-up observation examine preventive effect fracture risk .</brief_summary>
	<brief_title>Randomized , Open , Parallel , Active Controlled Study Fracture Prevention Antiosteoporosis Treatment ( OF Study )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Inpatient outpatient ask . If use antiosteoporotic agent calcium preparation ( i.e. , contraindicate concomitant use stipulate protocol postmarketing study ) , agent must discontinue . Even discontinuation , calcium dosing permit condition subsequent use start 8week elapse discontinuation . Patients primary osteoporosis ( diagnose accord `` Diagnostic Criteria Primary Osteoporosis issue Japanese Society Bone Mineral Research ( 1995 ) . '' Postmenopausal patient age 50 year old . Patients agree participate 4year followup observation . Patients provide write informed consent . Exclusion Criteira : Patients warfarin potassium ( WarfarinÂ® ) therapy . Patients hypercalcemia . Patietns renal calculus . Patients known history hypersensitivity calcium menatetrenone preparation . Patients severe complication hepatic , renal , gastrointestinal , cardio cerebrovascular system . Patients underwent bilateral ovariectomy . Patients radiotherapy pelvis paraaortic area . Patients follow Xray finding ; 1 . Patients show osteophyte connect adjacent vertebral osteophytes 2 . Patients show hyperostosis ligament around vertebral body 3 . Patients show interbody fusion 4 . Patients experience surgical intervention ( ) spine 5 . Patients scoliosis disturbs diagnose vertebral fracture Patients treat antiosteoporotic agent , calcium preparation , within 8 month prior study treatment ( applied following ; discontinue , nontreated , shift calcium monotherapy 8 week longer start study treatment ) . Patients experience bisphosphonates past . Patients likely show insufficient absorption liposoluble agent biliary atresia , impaired bile secretion , etc . Other patient judge ineligible study entry investigator investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>